EGFR and non-small cell lung carcinoma: Recent progress in the development of therapies targeting epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase rearrangements, and rare oncogenic drivers (such as ROS1, RET, MET, and EGFR exon 20 insertion mutations) has considerably improved the survival in a subset of patients with NSCLC [4,5].